With the development of the InBody, Biospace has explored new realms of body composition analysis, setting the standard for diagnosis of obesity and healthcare. Biospace’s
trailblazing activities in this area are evident in the label of “InBody test,” a commonly given body composition analysis that has recently increased in popularity.
The InBody uses the 8-point tactile electrode method and measures resistance in broadband frequencies of 1kHz- 1MHz and reactance in mean frequencies.
Its high quality and accuracy has been validated in many nations.
Biospace has lately introduced theupload-pressurized automatic sphygmomanometer BPBIO320 that provides accurate and less painful results. It increases the pressure only up to the patient’s systolic pressure for minimal discomfort. Core features of the BPBIO320 include automatic energy saving mode, compressor belt for user’s comfort, three color schemes and wide LED screen.
With the unparalleled performance of the InBody at home and abroad, Biospace has solidified its foundation as a professional medical device manufacturer. Currently, headquartered in Seoul, Korea, with overseas branches in the USA, Japan and China, the company has distributors in more than 40 countries.
● Biospace Co., Ltd.
518-10, Dogok 2-dong, Gangnam-gu, Seoul, Korea